30.42
Kymera Therapeutics Inc stock is traded at $30.42, with a volume of 425.50K.
It is down -2.91% in the last 24 hours and down -20.92% over the past month.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
See More
Previous Close:
$31.35
Open:
$31.66
24h Volume:
425.50K
Relative Volume:
0.83
Market Cap:
$1.98B
Revenue:
$87.56M
Net Income/Loss:
$-167.47M
P/E Ratio:
-13.00
EPS:
-2.34
Net Cash Flow:
$-148.20M
1W Performance:
-13.80%
1M Performance:
-20.92%
6M Performance:
-34.29%
1Y Performance:
-30.03%
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
KYMR
Kymera Therapeutics Inc
|
30.50 | 1.98B | 87.56M | -167.47M | -148.20M | -2.34 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
488.92 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
688.49 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
242.37 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
BNTX
Biontech Se Adr
|
112.68 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-10-24 | Initiated | BTIG Research | Buy |
Dec-06-24 | Initiated | BMO Capital Markets | Market Perform |
Dec-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Nov-18-24 | Initiated | Stephens | Overweight |
Sep-09-24 | Resumed | Leerink Partners | Outperform |
Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Apr-22-24 | Initiated | Oppenheimer | Outperform |
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Jun-30-23 | Initiated | Truist | Buy |
May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
Nov-08-22 | Initiated | Raymond James | Mkt Perform |
Aug-15-22 | Initiated | Jefferies | Buy |
Aug-03-22 | Initiated | Goldman | Buy |
Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
Apr-28-22 | Initiated | Credit Suisse | Outperform |
Mar-10-22 | Initiated | JP Morgan | Neutral |
Feb-10-22 | Initiated | Wells Fargo | Overweight |
Sep-30-21 | Initiated | B. Riley Securities | Neutral |
Sep-30-21 | Initiated | Stifel | Buy |
Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
May-21-21 | Initiated | UBS | Buy |
Apr-14-21 | Initiated | Berenberg | Buy |
Dec-04-20 | Initiated | H.C. Wainwright | Buy |
Sep-15-20 | Initiated | BofA Securities | Neutral |
Sep-15-20 | Initiated | Cowen | Outperform |
Sep-15-20 | Initiated | Guggenheim | Buy |
Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Q3 Earnings Forecast for KYMR Issued By HC Wainwright - Defense World
Analysts Set Expectations for KYMR Q2 Earnings - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Annual Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $60.00 at HC Wainwright - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Announces Earnings Results - MarketBeat
Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 13.9% on Disappointing Earnings - MarketBeat
(KYMR) Trading Signals - Stock Traders Daily
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Volatility Hits 9.22%: What Good Investors Need To Be Aware Of - Stocks Register
Kymera Therapeutics stock target cut to $54 by H.C. Wainwright - Investing.com Canada
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2024 Earnings Call Transcript - Insider Monkey
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus.com
Demystifying Kymera Therapeutics: Insights From 6 Analyst Reviews - Benzinga
We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate - Yahoo Finance
Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ... - Yahoo Finance
Kymera Therapeutics (NASDAQ:KYMR) Reaches New 52-Week Low After Earnings Miss - Defense World
Kymera Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks
Kymera stock hits 52-week low at $29.23 amid market challenges - Investing.com
Kymera stock hits 52-week low at $29.23 amid market challenges By Investing.com - Investing.com South Africa
Kymera Therapeutics misses Q4 estimates, shares dip By Investing.com - Investing.com Australia
Kymera Therapeutics misses Q4 estimates, shares dip - Investing.com
Kymera Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls -February 27, 2025 at 08:54 am EST - Marketscreener.com
Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
KYMERA THERAPEUTICS Earnings Results: $KYMR Reports Quarterly Earnings - Nasdaq
Earnings Flash (KYMR) Kymera Therapeutics Posts Q4 Revenue $7.4M, vs. FactSet Est of $14.4M - Marketscreener.com
Kymera Therapeutics, Inc. SEC 10-K Report - TradingView
Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
Can Kymera's $851M War Chest Deliver on Its Promising Immunology Pipeline Despite Widening Losses? - StockTitan
What To Expect From Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings - Yahoo Finance
Kymera Therapeutics to Participate in Upcoming March Investor Conferences - The Manila Times
Kymera Therapeutics Sets Investor Conference Calendar: Four Key Healthcare Events Where You'll Hear Their Story - StockTitan
Head to Head Analysis: Kymera Therapeutics (NASDAQ:KYMR) and Creative Medical Technology (NASDAQ:CELZ) - Defense World
Assured Guaranty, Kymera rise; BP, Helen of Troy fall, Tuesday, 7/9/2024 - MSN
Kymera Therapeutics (KYMR) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance - MSN
Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27 - The Manila Times
Kymera Therapeutics (KYMR) Expected to Announce Earnings on Thursday - Defense World
Kymera Therapeutics: Plenty Of Potential, But A Long Way From The Finish Line (KYMR) - Seeking Alpha
When the Price of (KYMR) Talks, People Listen - Stock Traders Daily
Getting In Cheap On Kymera Therapeutics, Inc. (NASDAQ:KYMR) Is Unlikely - Simply Wall St
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Kymera rises after presentation at the J.P. Morgan event - MSN
SG Americas Securities LLC Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Jennison Associates LLC Trims Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Head to Head Review: Kymera Therapeutics (NASDAQ:KYMR) & Gene Biotherapeutics (OTCMKTS:CRXM) - Defense World
Financial Snapshot: Analyzing Kymera Therapeutics Inc (KYMR)’s Key Ratio Metrics - The Dwinnex
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):